Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

124 results about "Modifying genes" patented technology

Modifying gene. a gene that alters or influences the expression function of another gene, including the suppression or reduction of the usual function of the modified gene. Also called modification allele. modifying gene. A gene that influences or alters the expression of other genes.

Systems and methods for multimodal conversational agents for biological sequence analysis

Provided herein are technologies for framing and evaluating biological sequence-based analysis tasks in a unified, natural-language-based, text in and text out format. Among other things, methods and systems of the present disclosure provide machine-learning technologies for combining biological sequence data, representing, for example, DNA, RNA, and protein sequences, with natural language, conversational style prompts that set out particular analysis tasks to be performed on the biological sequence data. This approach, for example, allows complex analysis tasks, including, but not limited to, identification of various sequence modifications, genes, and regulatory elements in DNA sequences, and quantification of properties such as degradation propensity of RNA and protein stability, to be input to a machine learning model in a uniform text-based format and for output to be generated in a same, unified, text-based format.
Owner:INSTADEEP LTD +1

Application of wheat transcription factor TaWRKY22 and coding gene thereof in regulation and control of plant stripe rust resistance

The invention belongs to the technical field of plant genetic engineering, and particularly relates to application of a wheat transcription factor TaWRKY22 and a coding gene thereof in regulation and control of plant stripe rust resistance. The function of the wheat transcription factor TaWRKY22 is researched through molecular biology and genetics methods, it is found that knockout of the TaWRKY22 gene significantly improves the resistance of wheat to stripe rust, overexpression of the TaWRKY22 gene reduces the resistance of wheat to stripe rust, and then it is indicated that the wheat transcription factor TaWRKY22 plays a negative regulation role in wheat stripe rust resistance. Therefore, the TaWRKY22 gene is subjected to targeted modification through a gene editing technology, a new genetic material and a molecular breeding strategy can be provided for wheat stripe rust resistance breeding, and an important material and technical support are provided for breeding of wheat disease-resistant varieties.
Owner:SHENZHEN RESEARCH INSTITUTE OF NORTHWEST A & F UNIVERSITY

Compositions and methods for targeting, editing, or modifying genes

CRISPR-Cas systems have been engineered for various purposes, such as genomic DNA cleavage, base editing, epigenome editing, and genomic imaging. Although significant developments have been made, there still remains a need for new and useful CRISPR-Cas systems as powerful precise genome targeting tools. The invention disclosed herein comprises CRISPR-Cas based methods for high integration and expression efficiency of transgenes together with high post-transfection cell viability in eukaryotic cells.
Owner:CELYNTRA THERAPEUTICS SA

Construction method and application of chlamydomonas reinhardtii-source high-sweetness protein variant engineering algal strain

The invention discloses a construction method and application of a chlamydomonas reinhardtii-sourced high-sweetness protein variant engineering algal strain, the construction method comprises the following steps: carrying out gene modification on sweeteners Thaumatin and Brazzein, optimizing preference codons of chlamydomonas reinhardtii to synthesize CrThaumatin and CrBrazzein encoding genes, cloning the encoding genes into an expression vector pGM6, introducing the recombinant expression vector into a chlamydomonas reinhardtii wild-type chlamydomonas sp. Algal strain, and carrying out high-sweetness protein variant engineering algal strain of the chlamydomonas reinhardtii-sourced high-sweetness protein variant engineering algal strain of the chlamydomonas reinhardtii. And screening by using a paromomycin resistance marker carried by the expression vector to successfully obtain an engineering algal strain. According to the present invention, the engineering strain is subjected to fermentation production to obtain the dry and stable Chlamydomonas reinhardtii powder rich in the target sweet protein, and the protein purification oral test results show that the sweet taste of the Chlamydomonas reinhardtii powder is 3-5 times of the sweet taste of the natural Thaumatin and Brazzein protein;
Owner:JIANGHAN UNIVERSITY

Engineering bacterium for synthesizing mannitol by using fructose and nicotinamide ribose and application of engineering bacterium

The invention relates to an engineering bacterium for synthesizing mannitol by using fructose and nicotinamide ribose and application thereof. The invention provides genetic recombination escherichia coli for synthesizing D-mannitol by using D-fructose and nicotinamide ribose, which comprises the following modifications: insertion or enhanced expression of a gene cluster 1, the gene cluster 1 comprises a D-mannitol dehydrogenase coding gene MDH and a formate dehydrogenase coding gene FDH; deletion or inhibitory expression of a gene cluster 2, wherein the gene cluster 2 comprises a 6-phosphofructokinase 1 coding gene pfkA; and insertion or enhanced expression of a gene cluster 3, wherein the gene cluster 3 comprises a nicotinamide ribokinase coding gene NRK, a nicotinamide mononucleotide adenosine transferase coding gene NMNAT, a polyphosphate kinase coding gene PPK2 and a pyrophosphohydrolase coding gene IPPa. The strain disclosed by the invention can effectively synthesize high-purity D-mannitol by using D-fructose as a production raw material and nicotinamide ribose as a co-substrate through an enzyme catalytic reaction under the condition of not additionally adding NAD < + > or NADP < + >, so that the production cost is greatly reduced.
Owner:MICROCYTO BIOTECHNOLOGY (BEIJING) CO LTD

Target-specific CRISPR mutant

The present invention relates to an artificially engineered CRISPR / Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR / Cas9 system including the same enzyme in genome and / or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.
Owner:TOOLGEN INC

Compositions and methods for targeting, editing, or modifying genes

Provided herein are nucleic acids useful as guide nucleic acids (gNAs), e.g., guide ribonucleic acids (gRNAs), in a CRISPR system wherein the guide nucleic acids contain one or more modifications to one or more nucleotides, use of such guide nucleic acids in modifying cells, and other uses wherein CRISPR Cas proteins are utilized.
Owner:CELYNTRA THERAPEUTICS SA

A recombinant Escherichia coli capable of efficiently producing monophospholipid A vaccine adjuvant

The present invention discloses a recombinant Escherichia coli capable of efficiently producing monophospholipid A vaccine adjuvant, belonging to the fields of genetic engineering and synthetic biology. The present invention knocks out 132 genes related to membrane wall surface molecules, phospholipid and glucose transport, phosphoethanolamine modification and enoyl-ACP reductase in Escherichia coli MG1655, expresses lipid A modification genes FnlpxE, SepagP and SepagL, and constructs strain MW021 / pTEPL. The growth performance of MW021 / pTEPL is greatly improved and antibiotics and inducers are no longer required during the fermentation process; in a 2-L fermentation tank system, the highest OD of MW021 / pTEPL growth is 600 It can reach 38.54, and can produce 13.84g / L of dry cells and about 88.99mg / L of total lipid A; total lipid A contains only two structures, namely MPL and D-MPLA.
Owner:JIANGNAN UNIV

DNA editing using single-stranded DNA

Disclosed are compositions, methods, and kits for modifying DNA within cells as well as compositions and methods for modifying gene expression in a cell. In particular, the invention generally relates to compositions, methods, and kits for DNA editing using single-stranded DNA. Compositions and methods for modifying gene expression using artificial microRNAs (amiRNA) are also contemplated.
Owner:BOARD OF RGT UNIV OF NEBRASKA +1

Method for preparing cell containing modified DNA, method for preparing organism containing said cell, and method for producing gene product

PCT designated stageWO2025182957A1FungiBacteriaNucleotidegenomic DNA
Provided is a means for constructing a modified genomic DNA which has a nucleotide sequence different from an existing genomic DNA sequence, contains a modified gene capable of expressing a polypeptide, a functional RNA, or both, and does not contain exogenous DNA. This method comprises: performing, at least twice, (a) a step for specifically cleaving genomic DNA of a cell into at least two target sequences by means of a sequence-specific nuclease, and linking the resultants through a DNA double-stranded cleavage repair by the cell; and deleting at least two regions from an existing gene and non-coding regions adjacent thereto to thereby produce a modified gene.
Owner:NICHIREI FOODS INC

Plant regulatory elements and uses thereof

PCT designated stage expiredWO2025122419A1HydrolasesStable introduction of DNABiotechnologyPlant cell
The disclosure provides novel synthetic small nuclear RNA (snRNA) promoters which are useful for CRISPR-mediated targeted gene modifications in plants. The disclosure also provides methods and compositions for use for the snRNA promoters driving expression of guide RNAs and non-coding RNAs for development of plants and plant cells comprising modified genomes.
Owner:MONSANTO TECHNOLOGY LLC

Application of lactic acid modified gene ENO1 inhibitor in preparation of medicine for treating nasopharynx cancer

The invention discloses application of a lactic acid modified gene ENO1 inhibitor in preparation of a medicine for treating nasopharynx cancer, and relates to the technical field of biological medicines. A head and neck squamous cell carcinoma prognosis model containing seven lactylation related genes is constructed by analyzing a TCGA database, the model can effectively distinguish patient risks, the total lifetime of a high-risk group is remarkably shortened, and a risk score is an independent prognosis factor; the functions of the key gene ENO1 are deeply studied through in-vitro experiments, and experimental results show that silencing of the ENO1 gene in nasopharynx cancer 5-8F cells causes up-regulation of cell pan-lactylation level, up-regulation of MMP2 expression and down-regulation of E-cadherin expression, and migration and invasion ability of tumor cells is significantly enhanced. The prognosis model provided by the invention has an important clinical prediction value, inhibition of ENO1 can promote tumor progression through abnormal lactylation, and a new thought is provided for taking ENO1 as a treatment target.
Owner:THE PEOPLES HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION

Modified plant

PCT designated stageWO2026042581A1Plant peptidesFermentationBiotechnologyTransgene
The present invention addresses the problem of providing a technique capable of haploid induction by enhancing the expression and / or function of a regulatory gene. The problem is solved by the use of a modified plant comprising an introduced or modified H2A.W gene, wherein said introduction or modification enhances the expression and / or function of the H2A.W gene in a germ cell.
Owner:NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST

Methods and compositions for LPA gene editing and therapy using crispr system

Compositions and methods for inducing a double-stranded break (DSB) within the LPA gene, and / or modifying the LPA gene are provided. Compositions and methods for treating diseases associated with LPA are provided.
Owner:GENEDITBIO LTD

Primer group, kit and detection system for thalassemia gene detection

PendingCN121472396AMicrobiological testing/measurementDNA/RNA fragmentationBeta thalassemiaThird generation sequencing
The invention discloses a primer group, a kit and a detection system for thalassemia gene detection. In order to more comprehensively and accurately detect point mutation, small insertion, small deletion, gene fusion mutation, large fragment deletion and gene structure variation on a thalassemia core gene and a modified gene in single detection, the invention provides a thalassemia gene detection primer group and a kit. Based on third-generation sequencing platforms such as a single-base nanopore sequencing platform and the like, all point mutation, small insertion, small deletion and gene fusion mutation in the amplification range of the thalassemia core gene and the modified gene can be detected by utilizing the primer group or the kit; and 60 alpha large fragment deletion mutations, 60 beta large fragment deletion mutations and 7 gene structure variations. The method is beneficial to rapid and comprehensive screening of thalassemia, and is high in detection sensitivity and good in accuracy.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)

Retinitis pigmentosa treatment

An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.
Owner:VISION PHARMA PTY LTD

Compositions and methods for use in immunotherapy

Provided herein are CasX:gNA systems, and compositions and methods relating thereto, the systems comprising CasX proteins, guide nucleic acids (gNAs), and optionally donor template nucleic acids useful for the modification cell genes encoding proteins involved in antigen processing, antigen presentation, antigen recognition, and / or antigen response, as well as methods of producing and using populations of cells comprising these modified genes. In some embodiments, the modified cells further express chimeric antigen receptors (CAR) or engineered T cell receptors (TCR). Such systems are useful for preparing cells for immunotherapy.
Owner:SCRIBE THERAPEUTICS INC

Modified gene vaccines against avian coronaviruses and methods of using the same

The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated NA vaccine compositions and viral vaccine compositions that encode an Infectious Bronchitis Virus (IB V) spike (S) protein, an IBV nucleocapsid (N) protein, or both the S protein and the N protein. Additionally, the present invention provides methods in which the disclosed vaccines are administered to a subject to induce an immune response against IBV or to vaccinate the subject against IBV.
Owner:WISCONSIN ALUMNI RES FOUND

Compositions and methods for modifying genomes

Compositions and methods for modifying genomic DNA sequences are provided. The methods produce double-stranded breaks (DSBs) at pre-determined target sites in a genomic DNA sequence, resulting in mutation, insertion, and / or deletion of DNA sequences at the target site(s) in a genome. Compositions comprise DNA constructs comprising nucleotide sequences that encode a Cms1 protein operably linked to a promoter that is operable in the cells of interest. The DNA constructs can be used to direct the modification of genomic DNA at pre-determined genomic loci. Methods to use these DNA constructs to modify genomic DNA sequences are described herein. Additionally, compositions and methods for modulating the expression of genes are provided. Compositions comprise DNA constructs comprising a promoter that is operable in the cells of interest operably linked to nucleotide sequences that encode a mutated Cms1 protein with an abolished ability to produce DSBs, optionally linked to a domain that regulates transcriptional activity. The methods can be used to up- or down-regulate the expression of genes at predetermined genomic loci.
Owner:CONFLUENCE GENETICS LLC +2

Primer group, method and kit for detecting thalassemia

The invention provides a primer group, a method and a kit for detecting thalassemia, which can be used for simultaneously detecting thalassemia related genes, related regulatory regions and modified gene mutations. According to the method, multiple regions and multiple mutations of HBA1, HBA2, HBB and other genes, related regulatory regions (LCR, 3 'HS, HS-40 and MCS-R) and modified genes (HBD, MYB, BCL11A and KLF1) are detected at the same time based on multiple PCR amplification and three-generation sequencing, amplification of related gene deletion type and non-deletion type mutations can be achieved at the same time in a single reaction tube through multiple PCR; a third-generation sequencing platform (an ONT sequencing platform and a PacBio company sequencing platform) is subsequently adopted for subsequent detection, the method is easy and convenient to operate, multiple PCR and a third-generation sequencing library are reliable in quality and high in repeatability, application of the third-generation sequencing technology to clinical detection is facilitated, and the method is suitable for clinical detection. According to the invention, various deletion and non-deletion mutation, complex structure variation and the like can be detected at the same time; when two or more mutations exist on the HBA1 / 2 or HBB gene locus at the same time, cis-mutation or trans-mutation can be distinguished.
Owner:YIKON GENOMICS (SUZHOU) CO LTD

Compositions and methods for angiopoietin like 3 (angptl3) editing

PCT designated stageWO2025184520A1DNA/RNA fragmentationDiseasePharmacology
The present disclosure provides compositions and methods for modifying an ANGPTL3 gene. In some aspects, the present disclosure provides a guide RNA, compositions thereof, and pharmaceutical compositions comprising a guide RNA or a composition as described herein. In some aspects, the present disclosure also provides uses and methods of using a guide RNA, a composition thereof, or a pharmaceutical composition as described herein, for inducing a double-stranded break in an ANGPTL3 gene, for reducing expression of an ANGPTL3 gene in a cell or subject, and for treating a patient having or at risk of having an ANGPTL3 -related disease or condition.
Owner:INTELLIA THERAPEUTICS INC

Method for manufacturing cell including modified genome DNA, and method for producing gene product

To provide means for constructing a modified DNA having a nucleotide sequence different from an existing genome DNA sequence, which is a modified genome DNA including a modified gene in which polypeptide, functional RNA or both can be expressed, but not including a foreign DNA.SOLUTION: A method includes (a) performing a step of cleaving a genome DNA of a cell in at least two target sequences more specifically by a sequence-specific nuclease, and connecting them by DNA double-strand break repair by a cell at least twice, deleting at least two regions from an existing gene and its adjacent non-encoded region to create a modified gene.SELECTED DRAWING: Figure 1A
Owner:NICHIREI FOODS INC

Histone demethylase gene OsJMJ708 for regulating and controlling rice salt stress toughness and application of histone demethylase gene OsJMJ708

The invention relates to the technical field of plant genes, in particular to a histone demethylase gene OsJMJ708 for regulating and controlling rice salt stress toughness and application, and the histone demethylase gene OsJMJ708 comprises the following steps: obtaining an OsJMJ708 mutant; identifying an editing target spot of the OsJMJ708 gene; the OsJMJ708 is planted in a water planting mode; carrying out salt stress tolerance identification on the OsJMJ708 mutant; a homozygous silent mutant genetic material is obtained based on a gene editing technology by taking a rice histone methylation modified gene OsJMJ708 as a target gene. And salt stress treatment is carried out by using 180mM NaCl. The result shows that after salt stress treatment, the OsJMJ708 knockout mutant shows a salt-tolerant phenotype. It is proved that the OsJMJ708 gene plays a negative regulation role in the rice salt stress process, and excellent gene information is provided for rice salt-alkali tolerance oriented molecular design breeding.
Owner:INST OF BOTANY CHINESE ACAD OF SCI

High-temperature-resistant phytase mutant as well as preparation method and application thereof

The invention belongs to the technical field of gene engineering and enzyme engineering, and particularly relates to a high-temperature-resistant phytase mutant as well as a preparation method and application thereof. The 19 , 104 and 305 genes of a phytase gene appA are modified to obtain a plurality of high-temperature-resistant phytase mutants, the heat resistance of the three mutants G19P / G104P / D305R is remarkably superior to that of wild type and traditional phytase, experimental results show that after the phytase mutants are respectively treated for 20 minutes at the high temperature of 80 DEG C, 90 DEG C and 100 DEG C, the residual rates of enzyme activity are respectively 94.6%, 91.8% and 66.5%, and the residual rates of enzyme activity are respectively 94.6%, 91.8% and 66.5%. The phytase can completely tolerate granulation at the high temperature of 80-95 DEG C in the feed industry, and the industrial pain point of insufficient enzyme activity after traditional phytase granulation is greatly solved.
Owner:JINAN TIANTIANXIANG

Antisense oligomer treatment for bone loss

Isolated or purified antisense oligomers, combinations, and cocktails for modifying premRNA splicing or mRNA translation in the SOST gene transcript or a portion thereof to induce downregulation of functional SOST protein production. Isolated or purified antisense oligomers are provided, as needed, for inducing the production of proteins with retained or partially retained introns, truncated proteins, proteins lacking functional regions, or a reduction in the total amount of protein produced.
Owner:PERRON INST FOR NEUROLOGICAL & TRANSLATIONAL SCI LTD

Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression

Disclosed are composition comprising (a) an inducible transgene construct, comprising a sequence encoding an inducible promoter and a sequence encoding a transgene, and (b) a receptor construct, comprising a sequence encoding a constitutive promoter and a sequence encoding an exogenous receptor, wherein, upon integration of the construct of (a) and the construct of (b) into a genomic sequence of a cell, the exogenous reporter is expressed, and wherein the exogenous reporter, upon binding a ligand, transduces an intracellular signal that targets the inducible promoter of (a) to modify gene expression. Methods for introducing compositions into cells and the use of the resultant cells in adoptive cell therapies are also provided.
Owner:POSEIDA THERAPEUTICS INC

CCA Gene For Virus Resistance

PendingUS20260185117A1BiotechnologyModifying genes
The present invention relates to a modified CCA gene which encodes a CCA-adding enzyme, which modified CCA gene leads to resistance against a positive-strand RNA virus having a transfer RNA-like structure (TLS). The invention further relates to plants and seeds comprising the modified genes, methods for making and identifying such plants and use of the gene.
Owner:RIJK ZWAAN ZAADTEELT & ZAADHANDEL BV

Application of chloroquine in improving gene editing efficiency

PendingCN122081398AImprove editing efficiencyImprove gene editing efficiencyFermentationVector-based foreign material introductionBiological materialsModifying genes
This invention discloses the application of chloroquine in improving gene editing efficiency. Specifically, it provides a novel use for chloroquine: enhancing the gene editing efficiency of gene editing reagents on recipient biological materials. The gene editing reagent is a gene editing tool plasmid. No prior art studies have combined chloroquine with gene editing efficiency. The inventors of this invention have discovered that treating recipient biological materials with chloroquine before transfecting them with gene editing reagents can significantly improve gene editing efficiency. This invention is simple to operate, widely applicable, and opens up a new avenue for improving editing efficiency by introducing exogenous small molecules rather than directly modifying gene editing tools.
Owner:CHINA AGRI UNIV

Application of hydroxychloroquine in improving gene editing efficiency

PendingCN122081397AImprove editing efficiencySimple and fast operationFermentationVector-based foreign material introductionHydroxychloroquineVersus gene
The invention discloses application of hydroxychloroquine to improvement of gene editing efficiency. The invention provides novel application of hydroxychloroquine, namely application of hydroxychloroquine in improving gene editing efficiency of a gene editing reagent on a receptor biological material. In the prior art, a research of combining hydroxychloroquine and gene editing efficiency is not seen. The inventor of the invention finds that the gene editing efficiency can be remarkably improved by treating a receptor biological material with hydroxychloroquine and then transfecting a gene editing reagent. The method is easy and convenient to operate and wide in applicability, and a new way for improving the editing efficiency is developed by introducing exogenous small molecules instead of directly modifying a gene editing tool. The invention provides a basis for exploring an editing efficiency improvement strategy by adding exogenous molecules instead of modifying an editor mutant.
Owner:CHINA AGRI UNIV

Methods for modifying a genome

Methods for modifying a genome are provided, wherein the modifications comprise null alleles, conditional alleles and null alleles comprising conditional by inversion elements. Methods are provided which afford the ability in a single targeting step to introduce an allele that can be used to generate a null allele, a conditional allele, or an allele that is a null allele and that further includes a conditional by inversion element. Introduced alleles comprise pairs of cognate recombinase recognition sites, an actuating sequence and / or a drug selection cassette, and a nucleotide sequence of interest, and a conditional by inversion element, wherein upon action of a recombinase a conditional allele with a conditional by inversion element is formed. In a further embodiment, action of a second recombinase forms an allele that contains only a conditional by inversion element in sense orientation. In a further embodiment, action by a third recombinase forms an allele that contains only the actuating sequence in sense orientation.
Owner:REGENERON PHARMACEUTICALS INC